Comparison of stage migration patterns between Europe and the USA: An analysis of 11 350 men treated with radical prostatectomy for prostate cancer

BJU International

Volumn 101, Issue 12, 2008, Pages 1513-1518

  Gallina, Andrea ^a,b   Chun, Felix K H ^a,c   Suardi, Nazareno ^a,b   Eastham, James A ^d   Perrotte, Paul ^d   Graefen, Markus ^c   Hutterer, Georg ^a,e   Huland, Hartwig ^c   Klein, Eric A ^f   Reuther, Alwyn ^f   Montorsi, Francesco ^b   Briganti, Alberto ^b   Shariat, Shahrokh F ^g   Roehrborn, Claus G ^g   De La Taille, Alexandre ^h   Salomon, Laurent ^h   Karakiewicz, Pierre I ^a,i  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF HAMBURG   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Intercontinental difference; Prostate cancer; Radical prostatectomy; Stage migration

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; EUROPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION MIGRATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; EUROPE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 43949124844     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07519.x     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30
2. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005 48 : 546 51
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993 270 : 948 54
4. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999 17 : 3167 72
5. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000 38 : 74 8
6. Steuber T, Graefen M, Haese A et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006 175 : 939 44
7. Gleason DF, Mellinger GT, Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging 1974. J Urol 2002 167 : 953 8
8. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 : 1445 51
9. Stephenson AJ, Scardino PT, Eastham JA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006 98 : 715 7
10. Ramirez A, Benayoun S, Briganti A et al. High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol 2006 50 : 58 63
11. Berglund RK, Jones JS, Ulchaker JC et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 2006 67 : 1253 6
12. Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006 50 : 70 5
13. Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 2000 36 : 1322 35
14. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006 175 : 907 12
15. Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005 97 : 1248 53
16. Smith EB, Frierson HF Jr., Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer 2002 94 : 2282 7
17. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 2003 56 : 1241 7
18. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol 2003 170 : 1189 93
19. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991-2001: changes in the pathologist's practice. Eur Urol 2005 47 : 196 201
20. Graefen M, Augustin H, Karakiewicz PI et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol 2003 43 : 6 11